01.002 RWE TNT May 2022 G 24-05-2022

Real-world evidence (RWE) solutions market predicted to be worth $3.13 billion by 2027

  • With a shift towards personalised healthcare and the rising emergence of rare diseases, healthcare and research organisations are facing challenges posed by high costs and lengthy timelines of delivering medicines to patients as the development of new pharmaceutical entities is time-consuming, extremely costly, and of high risk with little chance of successful outcome
  • As the COVID-19 outbreak continues to take its toll on global markets, real-world evidence (RWE) is set to become the most influential emerging technology to help in the fight against the COVID-19 outbreak as it provides valuable insights to understand better, monitor, and prepare for the challenges caused by the pandemic
  • Oncology accounted for the largest share in 2020 and is also expected to witness the fastest growth during the forecast period owing to the rising prevalence of cancer worldwide, growing R&D expenditure for cancer drugs, and increased adoption of RWE for innovation in oncology
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at